证券代码：688180 证券简称：君实生物 公告编号：临 2025-034 上海君实生物医药科技股份有限公司 关于根据一般授权配售新 H 股的公告 | 2023年年度股东 大会 | 指 | 本公司于2024年6月21日举行的2023年年度股东大会 | | --- | --- | --- | | A股 | 指 | 本公司股本中每股面值人民币1.00元的普通股，以人民 | | | | 币买卖并于上海证券交易所上市 | | A股股东 | 指 | A股持有人 | | 董事会 | 指 | 本公司董事会 | | 营业日 | 指 | 香港银行开放办理一般银行业务的任何日子（不包括 | | | | 星期六、星期日及香港公众假期） | | 交割 | 指 | 配售事项的交割 | | 交割日期 | 指 | 交割的日期，即2025年6月20日（或本公司与独家配售 | | | | 代理书面协议的其他有关时间及/或日期） | | 本公司 | 指 | 上海君实生物医药科技股份有限公司，一间于中国成 | | | | 立的股份有限公司，其H股及A股分别于香港联交所主 | | | | 板及上海证券交易所上市交易 | | 关连人士 | 指 | 具 ...

文件显示：君实生物寻求高达1.04亿美元的配售。 君实生物拟以每股25-26港元配售3140万股。 ...

Group 1 - The core viewpoint highlights a strong performance in the Chinese innovative pharmaceutical sector, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index rising by 2.72% as of June 12, 2025, driven by significant gains in constituent stocks such as Rongchang Bio (+17.55%) and BeiGene (+8.00%) [1] - A total of 53 new drugs were approved in China from the beginning of 2025 to the end of May, including 30 domestic innovative drugs and 23 imported ones, covering various therapeutic areas such as oncology and rare diseases [1] - The Chinese innovative drug market is projected to reach nearly 550 billion RMB in 2024, with an expected explosive growth driven by business development (BD) revenues from 2025 to 2027, and is anticipated to exceed 2 trillion RMB by 2030 [1] Group 2 - The Sci-Tech Innovation Board Biopharmaceutical Index consists of 50 large-cap companies from various sectors, including biopharmaceuticals and biomedical engineering, reflecting the overall performance of representative companies in the industry [2] - As of May 30, 2025, the top ten weighted stocks in the index accounted for 51.6% of the total index weight, with companies like United Imaging Healthcare and BeiGene among the leading constituents [2]

A股生物制品板块午后异动拉升，派林生物涨停，荣昌生物、长春高新、君实生物、百普赛斯、诺诚健 华等跟涨。 ...

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

Group 1 - Xinyu Securities clarified that it has not received any written or verbal information regarding a merger with Huafu Securities, and there are no significant undisclosed matters related to the merger [2] - Keda Li plans to jointly invest with Weichuang Electric and others to establish Suzhou Yizhi Intelligent Drive Technology Co., Ltd. with a registered capital of 50 million yuan, where Keda Li will contribute 15 million yuan for a 30% stake [2] - Shuangliang Energy signed a sales contract worth 450 million yuan for a green hydrogen production system, which is expected to positively impact the company's assets and net profit [3] Group 2 - Hesheng New Materials intends to invest 250 million yuan in Yizhi Electronics, acquiring a 10% stake in a company specializing in ARM server processor chips [4] - Junshi Biosciences received acceptance for a clinical trial application for JT118 injection, a vaccine aimed at preventing monkeypox virus infection [5] - Tinci Materials plans to invest approximately 2.8 million USD to build an integrated production base for electrolytes and raw materials in Morocco, with an annual production capacity of 150,000 tons [6] Group 3 - Beikong Technology's static and rolling P/E ratios are higher than the industry average, indicating potential overvaluation [7] - Qingdao Bank announced that Qingdao Guoxin Group intends to increase its stake in the bank to a maximum of 19.99% through its subsidiaries, pending regulatory approval [8] - Xiamen Airport reported an 8.34% year-on-year increase in passenger throughput for May, while Hubei Energy's power generation increased by 2.27% [9]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

Suspension and Resumption of Trading - *ST Yazhen has repeatedly triggered abnormal stock trading fluctuations and will be suspended for verification starting tomorrow [1] Investment Cooperation and Operating Conditions - Hesheng New Materials plans to invest 250 million yuan to increase its stake in Yizhi Electronics, expecting to hold 10% of the company post-investment. Yizhi Electronics specializes in the R&D, design, and sales of high-end processors for servers and workstations, providing chip product solutions [2] - Xingye Securities has not received any information regarding a merger with Huafu Securities [2] - Keda Li intends to jointly invest with Weichuang Electric to establish Suzhou Yizhi Intelligent Drive Technology Co., focusing on the market potential of embodied intelligent robots [2] - Tianfu Communication's 1.6T optical engine product is in a stable delivery phase, with smooth progress on related CPO products [2] - Shuangliang Energy has signed a sales contract for a 450 million yuan green hydrogen production system [2] - Junshi Biosciences' subsidiary JT118 injection clinical trial application has been accepted, aimed at preventing monkeypox virus infection [3] - Xingsen Technology plans to participate in the purchase of a 24% stake in its subsidiary Xinke Semiconductor [4] - Tianci Materials intends to invest approximately 280 million USD to build an integrated production base for electrolytes and raw materials in Morocco [5] - Shaanxi Construction has won a bid for a melamine project in Indonesia worth 2.137 billion yuan, with an annual production capacity of 120,000 tons [6] - Changyuan Donggu has received a notification from a well-known domestic automaker, confirming it as a designated supplier for a series of engine cylinder block semi-finished products, with total sales expected to be between 450 million and 500 million yuan [6]

近日，上海君实生物医药科技股份有限公司（以下简称"公司"）控股子公 司上海君拓生物医药科技有限公司收到国家药品监督管理局核准签发的《受理通 知书》，JT118 注射液（项目代号"JT118"）的临床试验申请获得受理。由于 药品的研发周期长、审批环节多，容易受到一些不确定性因素的影响，本次临床 试验申请能否获得批准存在不确定性，敬请广大投资者谨慎决策，注意防范投资 风险。现将相关情况公告如下： 一、药品基本情况 药品名称：JT118 注射液 证券代码：688180 证券简称：君实生物 公告编号：临 2025-033 上海君实生物医药科技股份有限公司 自愿披露关于 JT118 获得药物临床试验申请 受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 发。临床前研究结果表明，JT118 在大小动物上接种均可以产生高水平的结合抗 体、痘苗病毒/猴痘病毒中和抗体和细胞免疫激活，对痘苗病毒/猴痘病毒感染的 大小动物模型均具有显著的保护作用，且安全性良好。 2023 年 10 月，公司与北京大学、中国科学院微生物研究所、山 ...

Core Viewpoint - Junshi Bioscience's subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., has received acceptance for the clinical trial application of JT118 injection, a "dual-target" recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Company Summary - Junshi Bioscience (688180.SH) announced that its subsidiary has received the acceptance notice from the National Medical Products Administration for the clinical trial application of JT118 injection [1] - JT118 is composed of monkeypox virus antigens A35 and M1, designed as a "two-in-one" recombinant protein vaccine [1] - As of the announcement date, there are no approved vaccines for preventing monkeypox virus infection in China [1] Industry Summary - The development cycle for pharmaceuticals is lengthy and involves multiple approval stages, leading to uncertainty regarding the approval of this clinical trial application [1]